Ocrevus (Ocrelizumab)

Ocrevus is indicated for adults with relapsing forms of Multiple sclerosis, including clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive MS.  Ocrevus is also approved for Primary progressive Multiple Sclerosis. 

https://www.ocrevus.com/

Indication:

  • Multiple Sclerosis

    • Relapsing-remitting

    • Active Secondary progressing

    • Primary Progressive

Infusion Duration:

Frequency:

  • Dose 1: 300 mg

  • Dose 2: 300 mg week 2

  • Dose 3+: 600mg every 6 months